GH Research PLC
GH Research PLC (GHRS) Covered Calls
As of September 28, 2026, GHRS has 6 covered call opportunities in the coming three months. Return ranges from 8.9 to 50.7% until expiration. Annualized return ranges from 28.7 to 222.9%. The nearest expiration is November 20, 2026. Maximum potential profit is $1,188.
Read more
Running GHRS covered calls helps you generate consistent income from GH Research PLC's shares you already own, turning a long stock position into a yield-producing asset. A covered call on GH Research PLC involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best GHRS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if GHRS stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling GHRS covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given GH Research PLC covered call is worth writing.
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders.
GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Income-focused investors, long-term GHRS holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling GHRS covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best GH Research PLC covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile59.13% Neutral
- Market cap (M$)1,608
- 52 weeks high-25.51%
- 52 weeks low94.52%
- Analyst recommendationStrong Buy
1.00 - Target price$41.70
69.03% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-0.99
- EPS growth next 5 years—
As of September 28, 2026
| 2026-11-20 | 53 | 30.00 | 28.10 | 1.00 | 4.90 | 758.00 | 32.37 | 222.89 | -4.27 | +0.43 | 1 | 3.90 |
| 2027-01-15 | 109 | 30.00 | 28.10 | 0.20 | 4.90 | 678.00 | 28.95 | 96.94 | -0.85 | +0.40 | 17 | 4.70 |
| 2027-04-16 | 200 | 35.00 | 49.44 | 0.30 | 4.90 | 1188.00 | 50.73 | 92.57 | -1.28 | +0.37 | 1 | 4.60 |
| 2027-04-16 | 200 | 30.00 | 28.10 | 1.45 | 3.30 | 803.00 | 34.29 | 62.57 | -6.19 | +0.40 | 1 | 1.85 |
| 2027-01-15 | 109 | 25.00 | 6.75 | 0.50 | 4.90 | 208.00 | 8.88 | 29.74 | -2.13 | +0.51 | 6 | 4.40 |
| 2027-04-16 | 200 | 25.00 | 6.75 | 2.10 | 6.50 | 368.00 | 15.71 | 28.68 | -8.97 | +0.57 | 0 | 4.40 |
As of September 28, 2026
Sell covered calls with the data behind you
Find the best GHRS covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→